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ARTICLE HIGHLIGHTS    
 
Type of Research: single-center randomized controlled study 
 
Key Findings: The occlusion rate for MOCA at three years after GSV 
ablation is lower (82%) than for EVLA or RFA (both 100%). Veins with 
diameters of over 7 mm recanalized more often than those with smaller 
diameter. 
 
Take home Message: Though MOCA has some advantages over 
thermal ablation, the occlusion rate remains inferior at mid-term 
follow-up. 
 
Table of Contents Summary   
 
This randomized controlled study compares MOCA against thermal 
ablation in GSV insufficiency. At three years, the occlusion rates for 
MOCA are inferior to thermal ablation and it seems that veins with 









Mechanochemical ablation (MOCA) is a non-thermal non-tumescent method of treating saphenous 
vein insufficiency. The feasibility and short-term results of MOCA are good, but its long-term 
results are unknown. A randomized study was performed to compare MOCA with endovenous laser 
ablation (EVLA) and radiofrequency ablation (RFA) in the setting of unilateral GSV insufficiency. 
 
Methods 
Venous outpatient clinic patients with varicose veins (CEAP class C2-4) caused by GSV 
insufficiency were invited to participate in the study; in total, 132 patients filled the inclusion 
criteria and were willing to participate. Patients were randomized to treatment (2:1:1 for MOCA, 
EVLA, and RFA, respectively). The state of the GSV with duplex Doppler ultrasound examination 




Some patients declined to continue in the study after randomization; in total, 117 patients 
underwent treatment. At three years, the occlusion rate was significantly lower with MOCA than 
with either EVLA or RFA (82% vs. 100%, P = 0.005). Quality of life was similar between the 
groups. In the MOCA group, GSV’s that were preoperatively over 7 mm in diameter were more 
likely to recanalize during the follow-up period. The partial recanalizations of proximal GSV 





MOCA is a feasible treatment option for outpatient setting, but its technical success rates are 






In the treatment of superficial venous insufficiency, there has been a paradigm shift in the last 
decades. Open surgery has been all but abandoned in favour of minimally invasive endovenous 
techniques such as endovenous laser ablation (EVLA) and radiofrequency ablation (RFA). They 
have long-term occlusion rates of 88% or more in randomized controlled trials, confirming that they 
are at least equal to high ligation and stripping1-5. Thermal ablation (EVLA and RFA) is currently 
recommended as first choice of treatment for saphenous vein incompetence6. These techniques, 
however, require the use of tumescent anaesthesia and carry the risk of thermal injury to adjacent 
tissues. New, non-thermal non-tumescent techniques have been developed. These include 
mechanochemical ablation (MOCA) and cyanoacrylate closure. The safety and short-term efficacy 
of MOCA has been demonstrated7-13; however, data on longer-term results are insufficient14-16. We 
conducted a study comparing MOCA with EVLA and RFA in the treatment of great saphenous vein 
(GSV) insufficiency in a randomized setting.The one-year results have been published earlier, 
finding that MOCA produced a lower occlusion rate than EVLA or RFA17.  Here presented are the 




The study protocol and methods have been described in detail previously17. Briefly, in the years 
2014-2015, all patients referred to a vascular surgery clinic for treatment of varicose veins were 
screened for eligibility in this study, and those meeting the inclusion criteria were invited to 
participate. The inclusion criteria comprised clinical classification C2-C4, ultrasound-verified reflux 
of GSV in one leg with the mean GSV diameter in the thigh between 5 and 12 millimetres and age 
20-75 years. Patients with BMI over 40 kg/m2, peripheral arterial disease, lymphoedema, 
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pregnancy, allergy to either lidocaine or the sclerosant, severe general illness, previous varicose 
vein intervention in the same leg, or coagulation disorders were excluded. The study design was 
approved by the Ethics Committee of Helsinki University Hospital, and all participants provided 
written informed consent beforehand according to the principles of the Declaration of Helsinki.  
 
The primary outcome was the occlusion rate of the treated GSV at three years. The GSV was 
considered occluded, if no recanalized sections were observed in the ultrasound examination. 
Secondary outcomes consisted of disease-specific quality of life, clinical results measured with 
Venous Clinical Severity Score (VCSS)18, the need for additional treatment of the superficial veins 




A study nurse randomized the patients with the method of block randomization with sealed 
envelopes. The patients were randomized to three groups: EVLA, RFA, and MOCA in the ratio of 




The procedures have been described in detail in the one-year follow-up report17. Briefly, all patients 
were treated in a day-surgery unit. All procedures were done under ultrasound guidance. Thermal 
ablation procedures (EVLA and RFA) were done under local tumescent anaesthesia, and the 
patients received a light sedative (diazepam) before and during (propofol) the treatment, if 
necessary. In thermal ablation, the thigh part (from just below the knee to the groin) of the GSV was 
treated.  The laser fibre used for EVLA was a 1470-nm diode radial laser (ELVes®; Biolitec, Bonn, 
Germany) VNUS Closure FAST™ catheter (VNUS Medical Technologies, San Jose, California, 
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USA) was used in the RFA procedure. After thermal ablation, local phlebectomies were done under 
local anaesthesia through small skin incisions. In the MOCA group, ClariVein® catheter (Vascular 
Insights, Madison, Connecticut, USA) was used to induce occlusion in the GSV, accessing GSV at 
just below the knee, and liquid sodium tetradecyl sulphate (1.5%) was used as the sclerosant. After 
MOCA procedure, stab wound phlebectomies were done similarly to EVLA and RFA groups, with 
the aftercare being the same for all three treatment groups: a support stocking for two days 




At baseline, the patients completed the Aberdeen Varicose Veins Questionnaire (AVVQ) 19. The 
mean diameter of the GSV was documented before treatment both , at the proximal 20 cm and at 
the thigh. The clinical status of the venous disease was recorded with VCSS.  
 
At one- and three-year follow-up visits, the status of the GSV was investigated using duplex 
Doppler ultrasound imaging. All patients were examined by the same ultrasound qualified nurse. If 
at least 5 cm of compressible, patent vein was observed, the vein segment was considered to be 
partially recanalized.  Any additional varicosity treatment received during the follow-up was noted, 
as well as the need for such treatments. Nerve injuries, pigmentation, and clinical status (VCSS) 




According to sample size calculations, to detect a 20 per cent difference in GSV occlusion rate 
between the treatment groups with α = 0·05 and β = 0·8, the study would require 160 patients, 
accounting for 5 per cent of loss during the follow-up period.The data analysis was performed 
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according to intention-to-treat principle. One-way independent ANOVA was used for continuous 
variables with a normal distribution; when the distribution was skewed, Kruskal-Wallis test was 
applied. Comparison of categorical values was carried out with χ2 test, and the correlation between 
recanalization rate and the preoperative diameter of the GSV was calculated by binary logistic 
regression. Statistical analysis was done using SPSS® for Windows® versions 22.0-25.0 (IBM, 




In total, 125 patients met the inclusion criteria and received the allocated intervention. 117 patients 
attended the one-year follow-up, and 106 (84.8%) the three-year follow-up (figure 1). The patient 
attributes at the beginning of the study were similar between the treatment groups (table 1). There 
was one cross-over from MOCA to EVLA, all other patients received the allocated treatment. 
Phlebectomies were performed on 100% of the patients in the MOCA group, 94% of the patients in 




At the three-year follow-up, all patients treated with either EVLA or RFA had a completely 
occluded GSV, with no observed partial or total recanalization; the occlusion rate in these groups 
was 100%.  In the MOCA group 41 of 50 GSV´s were completely occluded, yielding an occlusion 
rate of 82 per cent (χ2 = 11,015, P = 0,005) (figures 2A-B). However, one patient in the MOCA 
group had already had re-treatment with EVLA at three years; the unassisted occlusion rate for 
MOCA is therefore 80 per cent. Kaplan-Meier estimate yielded a significant difference between the 




In the MOCA group, the preoperative diameter of the most proximal 20 cm of the GSV was 
strongly associated with recanalization of this segment at three years (odds ratio 1.95, 95% c.i. 1.09-
3.49, P = 0.024); odds of recanalization increased when the diameter increased (figure 4). Similarly, 
the diameter of the thigh trunk GSV correlated with recanalization of the trunk at three years (odds 
ratio 2.15, 95% c.i. 1.15-4.00, P = 0.016). Veins that had a preoperative diameter of over 7 
millimetres were more likely to recanalize during the follow-up period (figure 5): the occlusion rate 
was 100% for veins with a diameter of circa 6 mm, 87.5% for 7 mm and 75% for 8 mm. 
 
The partial recanalization observed in the proximal GSV at one-year follow-up led to further 




Disease-specific quality of life was measured with AVVQ and the clinical status with the VCSS. 
There were no differences between the groups at the baseline, and at three years, the quality of life 
had increased in all groups. Likewise, the clinical status had improved, with no significant 
differences between the treatment groups (figures 6-7). 
 
In the MOCA group, two patients had received additional treatment during the three-year follow-
up: one had laser ablation of the GSV (as mentioned above), and one sclerotherapy for GSV branch 
varicosities. At the point of three-year follow-up, two MOCA patients were in the queue for laser 
ablation of the GSV, and a few patients waited for consultation on their possible additional 
treatment. None of the patients in the EVLA and RFA groups had received additional treatment, but 




At three years, there were no patients in the MOCA group with symptoms of nerve injury. In the 
EVLA group, two patients had a sensory disturbance of an area under 10x10cm, one of them being 
in the ankle and other in the shin. In the RFA group, one patient had a small area of sensory 
disturbance in the thigh. All of these were present at one-year follow-up visit. One patient in the 
EVLA group reported a sensory disturbance of the medial ankle at one year, but this was no longer 




In the present paper we report the three-year results of a randomized controlled trial comparing 
mechanochemical GSV ablation with thermal ablation. GSV occlusion rate at 3 years was 
significantly better after thermal ablation than after MOCA, and a clear association of GSV calibre 
and recanalization was noted. In a recent meta-analysis, MOCA was equal to thermal ablation in the 
short term; the results of this study bring valuable information about the long-term effectiveness of 
MOCA16. 
 
The unassisted 3-year occlusion rate of the GSV was 80% in the MOCA group, a slightly lower 
figure than in most previous reports 8,10,11. However, the quality of life measured with disease-
specific instrument was equal between the three treatment groups. The study by Holewijn et al. 
likewise reports no significant differences in the quality of life between MOCA and other 
endovenous ablation methods a few years after the treatment10.  
 
A recent publication of the two-year results of a study comparing MOCA with RFA reports a 
closure rate of 80.0% after MOCA and hypothesizes that using polidocanol instead of STS might 
lead to more recanalization, and that treating the most proximal section on the GSV twice in case it 
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hasn’t collapsed after the first cycle might help prevent recanalization10. In the present study, STS 
was used in all patients, and according to the manufacturer’s instructions for use, the proximal 
section was treated twice if necessary. Still, the results are similar.  
 
According to these results, partial recanalization of the proximal GSV at one year often leads to full 
recanalization of either the whole or proximal GSV in the following two years. This indicates that 
partial recanalization after MOCA is important, even if asymptomatic, since it precludes complete 
recanalization and may result in need of additional treatment. Recanalization seems to be more 
likely in the larger veins with preoperative diameter of over 7 millimetres. There are no guidelines 
on the maximum vein size in MOCA, but according to a recent review, Clarivein® catheter can be 
used in veins with diameter of up to 20-24 mm: the rotating tip can in such veins still reach the vein 
wall20. The observed recanalization rate and the tendency of large veins to recanalize is comparable 
to the one-year results of this study17. Complete occlusion rate (with no recanalized areas of over 5 
cm) was not different at three years: 82% at one year, and 80% at three years. 
 
The advantage of MOCA is that it needs no tumescence, and the risk of nerve injury is minimal. In 
this study, some patients in the thermal ablation group reported a local sensory deficit at one year 
after the procedure. In this study, at three years, most of these patients still had the deficit, although 
the affected areas had generally diminished in size. MOCA is a faster method than thermal ablation 
and might be more feasible to use in the outpatient setting. Reportedly the pain scores and swelling 
are lower during and after the procedure than with thermal ablation10,21,22.  
 
This study is limited in that the inclusion criteria were very strict and therefore the patients included 
may not represent the real-life scope of patients requiring treatment for superficial venous 
insufficiency. Also, the patients and surgeons could not be blinded to the operation. The 
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concomitantly performed hook phlebectomies affect the pain scores and might also contribute to 
nerve injuries. There was one cross-over from MOCA to EVLA, but the analysis was made 
according to intention-to-treat principle; the treated vein remained occluded all through the study, 
and therefore it doesn’t lower the occlusion rate calculated for MOCA. The recruitment for the 
study was stopped before the target sample size was acquired, and thus the study may be 
underpowered. Although the attendance rate at three years was acceptable, the absolute of number 
of patients in each group was small and most of the treated veins had a preoperative diameter of 5 to 
7 millimetres. Our results suggest that veins with a diameter of over 7 mm tend to recanalize more 
often, but data from larger patient groups are needed to confirm the results before a definite 
recommendation on the maximum size can be made.  
 
We conclude that the three-year occlusion rates of MOCA are inferior compared to RFA or EVLA. 
Recanalization seems to be more common in veins with a preoperative diameter of over 7 
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